PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations

PCC-0208027 is a novel tyrosine kinase inhibitor that has a strong inhibitory effect on epidermal growth factor receptor (EGFR)- or HER2-driven cancers. The aim is to assess the anti-tumor activity of PCC0208027 and related mechanisms in non-small cell lung cancer (NSCLC). We examined the activity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Qiuju, Yu, Pengfei, Ye, Liang, Zhang, Jianzhao, Wang, Hongbo, Zou, Fangxia, Tian, Jingwei, Kurihara, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451005/
https://www.ncbi.nlm.nih.gov/pubmed/30952931
http://dx.doi.org/10.1038/s41598-019-42245-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451005/
https://www.ncbi.nlm.nih.gov/pubmed/30952931
http://dx.doi.org/10.1038/s41598-019-42245-3

Ejemplares similares